1152617-71-4Relevant articles and documents
Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8- trifluoromethyl[1,2,4]triazolo[4,3- a ]pyridine (JNJ-42153605): A positive allosteric modulator of the metabotropic glutamate 2 receptor
Cid, Jose María,Tresadern, Gary,Vega, Juan Antonio,De Lucas, Ana Isabel,Matesanz, Encarnación,Iturrino, Laura,Linares, María Lourdes,Garcia, Aránzazu,Andrés, José Ignacio,MacDonald, Gregor J.,Oehlrich, Daniel,Lavreysen, Hilde,Megens, Anton,Ahnaou, Abdellah,Drinkenburg, Wilhelmus,MacKie, Claire,Pype, Stefan,Gallacher, David,Trabanco, Andrés A.
, p. 8770 - 8789 (2013/01/15)
Advanced leads from a series of 1,2,4-triazolo[4,3-a]pyridines with mGlu2 receptor PAM activity are reported. By modification of the analogous imidazo[1,2-a]pyridine series, the newly reported leads have improved potency, in vitro ADMET, and hERG as well
IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
-
Page/Page column 64, (2009/06/27)
The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.